Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Irene M. Ghobrial"'
Autor:
Paul G, Richardson, Susanna J, Jacobus, Edie A, Weller, Hani, Hassoun, Sagar, Lonial, Noopur S, Raje, Eva, Medvedova, Philip L, McCarthy, Edward N, Libby, Peter M, Voorhees, Robert Z, Orlowski, Larry D, Anderson, Jeffrey A, Zonder, Carter P, Milner, Cristina, Gasparetto, Mounzer E, Agha, Abdullah M, Khan, David D, Hurd, Krisstina, Gowin, Rammurti T, Kamble, Sundar, Jagannath, Nitya, Nathwani, Melissa, Alsina, R Frank, Cornell, Hamza, Hashmi, Erica L, Campagnaro, Astrid C, Andreescu, Teresa, Gentile, Michaela, Liedtke, Kelly N, Godby, Adam D, Cohen, Thomas H, Openshaw, Marcelo C, Pasquini, Sergio A, Giralt, Jonathan L, Kaufman, Andrew J, Yee, Emma, Scott, Pallawi, Torka, Amy, Foley, Mariateresa, Fulciniti, Kyle, Hebert, Mehmet K, Samur, Kelly, Masone, Michelle E, Maglio, Andrea A, Zeytoonjian, Omar, Nadeem, Robert L, Schlossman, Jacob P, Laubach, Claudia, Paba-Prada, Irene M, Ghobrial, Aurore, Perrot, Philippe, Moreau, Hervé, Avet-Loiseau, Michel, Attal, Kenneth C, Anderson, Nikhil C, Munshi, Hillard, Lazarus
Publikováno v:
N Engl J Med
BACKGROUND: In patients with newly diagnosed multiple myeloma, the effect of adding autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib, and dexamethasone [RVD]), followed by lenalidomide maintenance therapy until
Autor:
Peter Sabbatini, Stacey Chuma, Rachid Baz, Jacob P. Laubach, Robert A. Redd, Alexandra Savell, Raymond P. Perez, Pamela S. Becker, Patrick Henrick, Kenneth C. Anderson, Oksana Zavidij, Chia Jen Liu, Kalvis Hornburg, Romanos Sklavenitis-Pistofidis, Michael Robbins, Kaitlen Reyes, Paul G. Richardson, Irene M. Ghobrial
Publikováno v:
Clinical Cancer Research. 26:344-353
Purpose: Ulocuplumab (BMS-936564) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12. Patients and Methods: This phase Ib/II study aimed to determine the safety and tolerability of ulocupl
Autor:
Irene M. Ghobrial
Publikováno v:
The Lancet Oncology. 21:1547-1549
Autor:
Philippe Armand, Damian R. Handisides, Irene M. Ghobrial, Jacalyn Rosenblatt, Kenneth C. Anderson, Jacquelyn Hedlund, Paul G. Richardson, Henry Dumke, Bradley Rivotto, Stacey Chuma, Robert L. Schlossman, Kenneth H. Shain, Stew Kroll, Patrick Henrick, Chia Jen Liu, Noopur Raje, Michael Gary Martin, Alexandra Savell, Andrew Yee, Craig Reynolds, Kalvis Hornburg, Laura Stampleman, Jacob P. Laubach, Ira Zackon
Publikováno v:
Clinical Cancer Research. 25:478-486
Purpose: The presence of hypoxia in the diseased bone marrow presents a new therapeutic target for multiple myeloma. Evofosfamide (formerly TH-302) is a 2-nitroimidazole prodrug of the DNA alkylator, bromo-isophosphoramide mustard, which is selective
Autor:
Youngil Koh, Lucie Lepine, Miles Prince, Valdas Peceliunas, Sevgi Kalayoglu Besisik, Irene M. Ghobrial, Codina Oprea, Emil Hermansen, Javier de la Rubia, Vania Hungria, Hang Quach, Paula Rodriguez-Otero, Maria-Victoria Mateos, Jin Seok Kim, Christine Devisme, Joaquin Martinez-Lopez, Sandrine Macé, Gurdeep Parmar, Xavier Leleu, Fredrik Schjesvold, Franck Dubin
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S109-S110
Background: High-risk smoldering multiple myeloma (HR-SMM) is associated with a greater risk of progression to symptomatic disease, suggesting the need for early, efficacious therapeutic interventions to improve outcomes. The ongoing, randomized Phas
Autor:
Omar Nadeem, Alexandra Distaso, Kelly Masone, Sarah Patches, Vaishali Sanchorawala, Paul G. Richardson, Giada Bianchi, Trevor J. Bayliss, Jacob P. Laubach, Isabella Hou, Robert A. Redd, Mary McKenney, Kenneth C. Anderson, Irene M. Ghobrial, Lindsay Issokson, Nikhil C. Munshi, Anna Barrell, Clifton C. Mo, Virginia Dalton, Peter Barth, Adam S. Sperling, Leyla Shune
Publikováno v:
Blood. 138:1650-1650
Introduction: Ixazomib is an oral proteasome inhibitor (PI) that is currently approved to be administered once weekly in combination with lenalidomide (LEN) and dexamethasone in RRMM (Moreau et al N Eng J Med 2016; 374:1621-1634). As most patients ar
Autor:
Irene M. Ghobrial, Omar Nadeem, Meredith Bertoni, Jacob P. Laubach, Rebekah Medina, Houry Leblebjian, Veronica Romines, Paul G. Richardson, Adam S. Sperling, Kelsey Tague, Alexandra Savell, Alexandra Distaso, Julia Prescott, Clifton C. Mo, Robert A. Redd, Amada Metivier
Publikováno v:
Blood. 138:4782-4782
Background: Early therapeutic intervention with lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma (HR-SMM) has shown to be effective by delaying time to progression to overt myeloma (Lonial J Clin Oncol 2020 Apr 10
Autor:
Ofer Shpilberg, Irene M. Ghobrial, Moshe Mittelman, Ashraf Badros, Ivan Spicka, Arnon Nagler, Kenneth C. Anderson, Richard Leblanc, Jacob P. Laubach, Kihyun Kim, Teru Hideshima, Peter Sportelli, Paul Blake, Paul G. Richardson, Moshe E. Gatt, Merav Leiba, Sung-Soo Yoon, Michael Chen, Kathleen Colson, Roman Hájek, Hakan Kaya, Joaquin Martinez-Lopez, Parameswaran Hari, Dina Ben-Yehuda
Publikováno v:
EJHaem. 1(1)
Perifosine, an investigational, oral, synthetic alkylphospholipid, inhibits signal transduction pathways of relevance in multiple myeloma (MM) including PI3K/Akt. Perifosine demonstrated anti-MM activity in preclinical studies and encouraging early-p
Autor:
Lorenzo Trippa, Jacob P. Laubach, Paul G. Richardson, Elizabeth O'Donnell, Kathleen J. Lively, Robert L. Schlossman, Tianqi Chen, Irene M. Ghobrial, Andrew Yee, Philip M. Wade, Carol Ann Huff, Frank G. Basile, Nikhil C. Munshi, Jill N. Burke, Claudia E. Paba-Prada, Kenneth C. Anderson, Hannah Lyons, Cynthia C. Harrington, Noopur Raje
Publikováno v:
British Journal of Haematology. 182:222-230
We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant-ineligible multiple myeloma (MM) patients. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population a
Autor:
Gullu Gorgun, Michelle E. Maglio, Cindy Varga, Constantine S. Mitsiades, Irene M. Ghobrial, Noopur Raje, Anna Guidetti, Mary McKenney, Robert L. Schlossman, Claudia Paba Prada, Paul G. Richardson, Kenneth C. Anderson, Nikhil C. Munshi, Teru Hideshima, Deborah Doss, Jacob P. Laubach
Publikováno v:
Expert Opinion on Orphan Drugs. 2:1089-1108
Introduction: Multiple myeloma patients who are refractory to lenalidomide and bortezomib have a dismal prognosis. Pomalidomide is a new immunomodulatory agent approved for the treatment of relapsed and refractory multiple myeloma (RRMM) that is uniq